Fig. 14

Oral administration of dasatinib daily for 2 weeks significantly downregulates LPS-stimulated IL-6 level in wild-type mice. a, c Wild-type mice were injected with dasatinib (20 mg/kg, p.o.) or vehicle (4% DMSO + 30% PEG + 5% Tween 80, i.p.) daily for 2 weeks, followed by injection with LPS (10 mg/kg, i.p.) or PBS. Three hours after LPS or PBS injection, immunohistochemistry was conducted with an anti-COX-2 antibody. b Quantification of the data shown in a (cortex: con, n = 8 mice; LPS, n = 8 mice; dasatinib+LPS, n = 8 mice). d–f Quantification of the data shown in c (hippocampus: con, n = 8 mice; LPS, n = 8 mice; dasatinib+LPS, n = 8 mice). One-way ANOVA with Tukey’s post hoc test was used to analyze significant differences. *p < 0.05, **p < 0.01, ***p < 0.001